Millipore Sigma Vibrant Logo

MABS1329 Anti-Annexin A3 Antibody, clone 9996-1-3M1/3L7-5

View Products on
100 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
Limited Quantities Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers


      Contact Customer Service


      Replacement Information

      Key Specifications Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HWB, IH(P), Neutralization AssayMPurifiedMonoclonal Antibody
      Catalogue NumberMABS1329
      DescriptionAnti-Annexin A3 Antibody, clone 9996-1-3M1/3L7-5
      Alternate Names
      • Annexin A3
      • 35-alpha calcimedin
      • Annexin III
      • Annexin-3
      • Inositol 1
      • 2-cyclic phosphate 2-phosphohydrolase
      • Lipocortin III
      • PAP-III
      • Placental anticoagulant protein III
      Background InformationAnnexin A3 (UniProt P12429; also known as 35-alpha calcimedin, Annexin III, Annexin-3, Inositol 1,2-cyclic phosphate 2-phosphohydrolase, Lipocortin III, PAP-III, Placental anticoagulant protein III) is encoded by the ANXA3 (also known as ANX3) gene (Gene ID 306) in human. Annexin A3 is a Ca2+-dependent phospholipid-binding protein shown to promote angiogenesis and rat liver regeneration. Upregulated annexin A3 expression is reported in ovarian, breast, colon, lung, gastric, gallbladder, testicular, and urothelial cancers, where it is involved in promoting tumorigenesis and resistance to chemotherapy. ANXA3 is reported to represent the most significantly upregulated gene that encodes for a secretory protein in the CD133+ liver cancer stem cell (CSC) subset. Both cellular and secretory annexin A3 play pivotal roles in promoting cancer and stem cell-like features in CD133+ liver CSCs through a dysregulated JNK pathway. Annexin A3 serum levels in hepatocellular carcinoma (HCC) patients are closely associated with aggressive clinical features. Annexin A3 neutralizing antibody is shown to cause a significant reduction in HCC tumor growth and self-renewal by effectively killing off CD133+ CSCs both in cultures in vitro and in animal xenograft in vivo.
      Product Information
      PresentationPurified mouse IgG1 in Tris-buffered saline (TBS) containing 50 mM tris-HCl (pH7.5) and 150 mM NaCl without preservatives.
      Quality LevelMQ100
      ApplicationDetect Annexin A3 using this mouse monoclonal Anti-Annexin A3 Antibody, clone 9996-1-3M1/3L7-5, Cat. No. MABS1329, validated for use in Immunohistochemistry (Paraffin) Neutralization, and Western Blotting.
      Key Applications
      • Western Blotting
      • Immunohistochemistry (Paraffin)
      • Neutralization Assay
      Application NotesImmunohistochemistry Analysis: A 1:250 dilution from a representative lot detected Annexin A3 in human placenta tissue sections.

      Western Blotting Analysis: 10 µg/mL from a representative lot detected Annexin A3 in 10 µg of human spleen tissue lysate.

      Immunohistochemistry Analysis: A representative lot detected a markedly downregulated annexin A3 immunoreactivity in Huh7 xenografts from antibody-treated mice, while an upregulated annexin A3 immunoreactivity was seen in xenografts from Cisplatin-treated mice (Tong, M., et al. (2015). Stem Cell Reports. 5(1):45-59).

      Neutralizing Analysis: A representative lot inhibited the proliferation of CD133-/annexin A3-positive Huh7 cells, but not the CD133-/annexin A3-negative MIHA cells. Antibody treatment further sensitized Huh7 to Cisplatin (Cat. No. 232120) antiproliferative activity (Tong, M., et al. (2015). Stem Cell Reports. 5(1):45-59).

      Neutralizing Analysis: A representative lot suppressed the migration, invasion, angiogenesis induction, and hepatospheres formation of human hepatocellular carcinoma (HCC) cells (Tong, M., et al. (2015). Stem Cell Reports. 5(1):45-59).

      Neutralizing Analysis: A representative lot inhibited the growth of Huh7 xenograph in mice. Residual xenografts following antibody treatment (alone or with Cisplatin), but not Cisplatin treatment alone failed to form tumor mass when serially transplanted into secondary recipients (Tong, M., et al. (2015). Stem Cell Reports. 5(1):45-59).

      Western Blotting Analysis: A representative lot detected the expression of the ~33 kDa Annexin A3 among a panel of human hepatocellular carcinoma (HCC) cell lines (Tong, M., et al. (2015). Stem Cell Reports. 5(1):45-59).
      Biological Information
      ImmunogenRecombinant human annexin A3.
      ConcentrationPlease refer to lot specific datasheet.
      SpecificityThis monoclonal antibody detected a single ~33 kDa target band among a panel of human hepatocellular carcinoma (HCC) cell lines. The epitope has been mapped to a 10-a.a. region within the third annexin domain (Tong, M., et al. (2015). Stem Cell Reports. 5(1):45-59).
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Gene Symbol
      • ANXA3
      • ANX3
      Purification MethodAffinity purified.
      UniProt Number
      Molecular Weight~33 kDa observed. 36.24 kDa calculated (Met1 removed). Uncharacterized bands may be observed in some lysate(s).
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceEvaluated by Western Blotting in human placenta tissue lysate.

      Western Blotting Analysis: 5 µg/mL of this antibody detected Annexin A3 in 10 µg of human placenta tissue lysate.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at -20°C from date of receipt.
      Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information